DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x8lrvm/epicast_report) has announced the addition of the "EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024" report to their offering.
Ankylosing spondylitis (AS) - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis (SpA) and one of the most common rheumatic diseases across the globe. AS primarily affects the spine and sacroiliac (SI) joints and progresses into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. AS that occurs before any structural changes in the spine is referred to as non-radiographic axial spondyloarthritis (nr-axSpA) which is the early stage of AS. Some of non-radiographic axial spondyloarthritis progress to AS and some do not.
The diagnosed prevalent cases of AS in the 7MM in the base scenario increased from 1,045,903 diagnosed prevalent cases in 2014 to 1,067,905 diagnosed prevalent cases in 2024, with an annual growth rate (AGR) of 0.21%. The forecast in the alternate scenario based on primary research data showed that there will be a substantial increase in the diagnosed prevalent cases of AS in the 7MM from 1,279,010 diagnosed prevalent cases in 2014 to 2,230,825 diagnosed prevalent cases in 2024, at an AGR of 7.44%. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.
Scope
- The Ankylosing Spondylitis EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for ankylosing spondylitis (AS) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of ankylosing spondylitis segmented by sex, age (in ten-year increments beginning at 15 years and ending at =65 years), and diagnosed prevalent cases of non-radiographic axial spondyloarthritis, and diagnosed prevalent cases of AS segmented by HLA-B27 seropositivity status in these markets.
- The ankylosing spondylitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Key Topics Covered:
1 Tables & Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.4 Forecast Methodology
3.5 Epidemiological Forecast for AS (2014-2024) - Base Scenario
3.6 Epidemiological Forecast for AS (2014-2024) - Alternative Scenario
3.7 Discussion
4 Appendix
For more information visit http://www.researchandmarkets.com/research/x8lrvm/epicast_report
